Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab

Citation: Gargiulo L, Toso F, Ibba L, Valenti M, Costanzo A, Narcisi A. Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab. Dermatol Pract Concept. 2023;13(2):e2023103. DOI: https://doi.org/10.5826/dpc.1302a103

Accepted: September 26, 2023; Published: April 2023

Copyright: ©2023 Gargiulo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.

Funding: None.

Competing interests: Antonio Costanzo has been a consultant and/or speaker for Abb-Vie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Galderma, Boehringer, Novartis, Pfizer, Sandoz, and UCB. Alessandra Narcisi has been a consultant and/or speaker for Abb-Vie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Boehringer, Novartis, Pfizer and UCB.  Mario Valenti has been a consultant and/or speaker for, Leo Pharma, Eli Lilly, Boehringer and Sanofi. Luigi Gargiulo, Francesco Toso and Luciano Ibba have nothing to disclose.

Authorship: All authors have contributed significantly to this publication.

Corresponding author: Dr. Francesco Toso, MD, Dermatology Unit, Department of Biomedical Sciences IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy. Tel: +39 0282244050 Email: francesco.toso@humanitas.it

Abstract

Keywords : psoriasis, acrodermatitis continua of Hallopeau, ixekizumab, ustekinumab, biologics

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

1. Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799. doi:10.1111/jdv.14386 2. Maliyar K, Crowley EL, Rodriguez-Bolanos F, O'Toole A, Gooderham MJ. The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review. J Cutan Med Surg. 2019;23(4):428-435. doi:10.1177/1203475419836435 3. Miller AC, Holland TE, Cohen DJ. Treatment of acrodermatitis continua of hallopeau with ixekizumab. J Dermatolog Treat. 2021;32(1):117-119. doi:10.1080/09546634.2019.1628170 4. Narcisi A, Valenti M, Cortese A, et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228. doi:10.1111/dth.15228 5. Husson B, Barbe C, Hegazy S, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2020;34(10):2330-2338. doi:10.1111/jdv.16265 6. Gargiulo L, Pavia G, Ibba L, et al. Generalized Pustular Psoriasis and Plaque Psoriasis Successfully Treated With Ixekizumab. Clin Exp Dermatol Ther. 2022; 7: 183. doi: 10.29011/2575-8268.100183. Published online ahead of print.